middle.news
How NIH’s Technegas® Contract Could Transform Cyclopharm’s US Market Strategy
12:12pm on Monday 9th of March, 2026 AEDT
•
Healthcare
Read Story
How NIH’s Technegas® Contract Could Transform Cyclopharm’s US Market Strategy
12:12pm on Monday 9th of March, 2026 AEDT
Key Points
NIH contract deemed strategically material but not financially material alone
Technegas® approved for clinical use at NIH with binding supply contract
46 US revenue-generating Technegas® sites with target of 250-300 by late 2026
Contract includes supply, installation, training, and recurring consumables revenue
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CYCLOPHARM (ASX:CYC)
OPEN ARTICLE